SCHEMBL15206787

SCHEMBL15206787

COc1ccc(Nc2nc3c(-c4ccc(C#N)nc4)nccn3n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 0.48
JAK3 P52333 9/20 0.48
PTK2 Q05397 5/20 0.48
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CDK1 P06493 2/20 0.44
KDR P35968 2/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 3/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
AURKA O14965 1/20 0.41
GFER P55789 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15207034 0.92 JAK2 (0.40) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL19607 0.90 SYK (0.40) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL15207711 0.89 PIK3CA (0.45) JAK2GAAMAPTAURKA
SCHEMBL15207896 0.88 CHEK1 (0.40) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL19101 0.87 TRPA1 (0.44) JAK2JAK3PTK2
SCHEMBL15207680 0.87 CHEK1 (0.36) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL21119 0.87 JAK2 (0.52) JAK2JAK3PTK2ALDH1A1GAA
SCHEMBL31418 0.86 MAPT (0.41) MEN1KMT2AGAAMAPTLMNA
SCHEMBL19931 0.86 JAK2 (0.50) JAK2JAK3PTK2ALDH1A1GAA
SCHEMBL19495 0.86 JAK2 (0.49) JAK2JAK3PTK2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 JAK2 5/4885JAK3 32/4885PTK2 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.